Nicholas Hall is proud to introduce its newest product OTC DASHBOARD, the first of its kind in the OTC world. Nicholas Hall’s OTC DASHBOARD is an innovative web applet designed to keep consumer healthcare executives connected with the latest industry trends; ultimately aiding their daily business decisions. Designed with the user in mind, the platform enables subscribers to access a wealth of reliable data, expert insight and facts from around the world, quickly and easily.Register now for a free trial
Access facts and data from 62 countries across 5 regions with additional detail for the top 20 markets
A quick summary of global, regional, and country market performance.
Country, regional and global forecasts show projected 1-, 2-, 5- and 10-year sales, simple growth and CAGR.
Summaries of the Top Marketers with snapshots of quarterly MAT data and provisional company OTC sales once Company Results are published.
Keeping you up-to-date with how each of the major OTC categories is performing.
Keep track of the top non-prescription brands, globally, regionally and in our Top 20 countries.
Provides a quick glance at the regulatory landscape surrounding OTCs.
An overview of the general distribution environment in each of our 62 countries.
Our collection of ready-to-use charts, graphs and infographics.
Quarterly profiles of a selection of dynamic growth brands, brands in decline, and the annual Top 10 growth companies.
A quarterly selection of ads supporting OTC brands from around the world.
Keep informed about the most important dates and events on the OTC calendar.
Make OTC DASHBOARD your own by saving your favourite regions and useful content in this area for later use.
An outstanding offering. I started OTC global marketing in 1990 and (after working in Rx global marketing) I was surprised to find my first challenge in OTC's was NO DATA. We had large businesses in many countries and almost no business in many others. The challenge I had was where to focus. Which categories, which countries offered the best growth opportunities? After months of data gathering it became clear to me that our focus was wrong if we wanted a much greater level of growth. The next challenge was proving this because big investment decisions require a lot of evidence. We have come a long way in understanding the world of OTC thanks to the Nicholas Hall team.
Joe McGovern. VP, Strategy at everythingHEALTH, USA